Integral Health Asset Management LLC Trims Stock Holdings in Boston Scientific Corporation $BSX

Key Points

• Integral Health Asset Management LLC trimmed its stake in Boston Scientific by 45.5% in Q3, selling 250,000 shares and leaving 300,000 shares worth $29.29 million (about 2.0% of its portfolio and its 8th largest holding).
• Multiple plaintiff law firms have filed or issued alerts alleging executives misrepresented U.S. electrophysiology procedure volumes, raising class-action litigation and settlement risk (lead‑plaintiff motions due May 4, 2026).
• CEO Michael F. Mahoney sold 160,901 shares for roughly $15.04 million (a 10.23% cut to his ownership), while several analysts trimmed price targets though consensus remains a Moderate Buy with an average target of $108.

Integral Health Asset Management LLC lessened its position in Boston Scientific Corporation (NYSE:BSX - Free Report) by 45.5% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 300,000 shares of the medical equipment provider's stock after selling 250,000 shares during the period. Boston Scientific accounts for about 2.0% of Integral Health Asset Management LLC's portfolio, making the stock its 8th biggest holding. Integral Health Asset Management LLC's holdings in Boston Scientific were worth $29,289,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of BSX. Vanguard Group Inc. boosted its stake in shares of Boston Scientific by 0.8% during the third quarter. Vanguard Group Inc. now owns 138,249,447 shares of the medical equipment provider's stock valued at $13,497,294,000 after purchasing an additional 1,115,337 shares in the last quarter. State Street Corp increased its stake in shares of Boston Scientific by 1.1% in the second quarter. State Street Corp now owns 65,191,864 shares of the medical equipment provider's stock valued at $7,002,258,000 after buying an additional 713,379 shares during the period. Norges Bank bought a new position in Boston Scientific in the 2nd quarter valued at approximately $2,089,937,000. Invesco Ltd. boosted its position in Boston Scientific by 0.7% during the 3rd quarter. Invesco Ltd. now owns 16,963,344 shares of the medical equipment provider's stock worth $1,656,131,000 after buying an additional 111,826 shares during the period. Finally, Legal & General Group Plc boosted its position in Boston Scientific by 4.6% during the 3rd quarter. Legal & General Group Plc now owns 10,457,175 shares of the medical equipment provider's stock worth $1,020,934,000 after buying an additional 463,889 shares during the period. 89.07% of the stock is currently owned by institutional investors.

Key Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Neutral Sentiment: Zacks published a recap explaining why Boston Scientific dipped more than the broader market, noting recent volatility around the company. Useful for context on short‑term market reaction. Article Title
• Negative Sentiment: Citigroup lowered its price target for Boston Scientific to $94.00 — a formal analyst downgrade that can weigh on sentiment and may lead some funds to reprice positions. Article Title
• Negative Sentiment: Levi & Korsinsky (reported via PR Newswire) and others say a filed class action alleges Boston Scientific executives misrepresented U.S. electrophysiology procedure volumes — this is the substantive allegation that could lead to discovery, potential damages or settlement risk. Investors should watch pleadings and any company response. Article Title
• Negative Sentiment: Multiple plaintiff law firms (Rosen, Pomerantz, Glancy Prongay Wolke, Robbins Geller, Faruqi, Gross, Bernstein Liebhard, etc.) have issued shareholder alerts and deadline reminders (lead‑plaintiff motions due May 4, 2026). The coordinated outreach increases the likelihood of consolidated litigation and underscores ongoing legal scrutiny. Article Title

Insider Activity

In related news, CEO Michael F. Mahoney sold 160,901 shares of the stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the transaction, the chief executive officer directly owned 1,411,735 shares of the company's stock, valued at $131,983,105.15. This represents a 10.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.50% of the stock is owned by insiders.

Analyst Ratings Changes

Several equities analysts have issued reports on the stock. TD Cowen decreased their price target on shares of Boston Scientific from $115.00 to $100.00 and set a "buy" rating for the company in a research report on Monday, February 2nd. Stifel Nicolaus cut their price target on shares of Boston Scientific from $125.00 to $110.00 and set a "buy" rating on the stock in a report on Wednesday, February 4th. Wall Street Zen raised shares of Boston Scientific from a "hold" rating to a "buy" rating in a research note on Saturday. UBS Group decreased their price objective on Boston Scientific from $140.00 to $120.00 and set a "buy" rating for the company in a report on Thursday, February 5th. Finally, Evercore lowered their target price on Boston Scientific from $112.00 to $96.00 and set an "outperform" rating for the company in a research report on Thursday, February 5th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, Boston Scientific presently has an average rating of "Moderate Buy" and an average price target of $108.00.

Boston Scientific Trading Up 0.9%

Shares of BSX stock opened at $69.15 on Friday. Boston Scientific Corporation has a fifty-two week low of $67.56 and a fifty-two week high of $109.50. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.08 and a current ratio of 1.62. The stock has a 50 day simple moving average of $82.47 and a two-hundred day simple moving average of $93.39. The company has a market cap of $102.61 billion, a P/E ratio of 35.64, a PEG ratio of 0.96 and a beta of 0.69.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.78 by $0.02. The firm had revenue of $5.29 billion for the quarter, compared to analysts' expectations of $5.29 billion. Boston Scientific had a return on equity of 19.63% and a net margin of 14.44%.The company's revenue for the quarter was up 15.9% compared to the same quarter last year. During the same period in the prior year, the business earned $0.70 EPS. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. Research analysts forecast that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Boston Scientific Profile

Boston Scientific Corporation NYSE: BSX is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific's activities span product development, clinical research, regulatory affairs and commercial sales.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.